MovDisordV3, PubMed, Curation, bibRecord, 001D25

Serotonin and Parkinson's disease: On movement, mood, and madness.

Identifieur interne : 001D25 ( PubMed/Curation ); précédent : 001D24; suivant : 001D26

Serotonin and Parkinson's disease: On movement, mood, and madness.

Auteurs : Susan H. Fox [Canada] ; Rosalind Chuang ; Jonathan M. Brotchie

Source :

Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.

RBID : pubmed:19412960

English descriptors

KwdEn :
- Affect (physiology), Animals, Dyskinesia, Drug-Induced, Humans, Mental Disorders (complications), Mental Disorders (metabolism), Movement (physiology), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson Disease (physiopathology), Serotonin (metabolism), Serotonin Agents (adverse effects), Serotonin Agents (therapeutic use).
MESH :
- chemical , adverse effects : Serotonin Agents.
- chemical , metabolism : Serotonin.
- complications : Mental Disorders.
- drug therapy : Parkinson Disease.
- metabolism : Mental Disorders, Parkinson Disease.
- physiology : Affect, Movement.
- physiopathology : Parkinson Disease.
- chemical , therapeutic use : Serotonin Agents.
- Animals, Dyskinesia, Drug-Induced, Humans.

Abstract

An appreciation of the multiple roles that serotonin (5-HT) may play in Parkinson's disease (PD) has increased in recent years. Early pathological studies in PD demonstrated nonselective reductions of 5-HT in brain tissue but little correlation to comorbidities such as dyskinesia and mood disturbance. This, combined with treatment failures using serotonergic drugs in comparison to levodopa, meant the field was largely neglected until recently. The multitude of subtypes of 5-HT receptors in the brain and an increased understanding of the potential function 5-HT may play in modulating other neurotransmitter systems, including dopamine, GABA, and glutamate, have meant an expansion in efforts to develop potential serotonergic drugs for both motor and nonmotor symptoms in PD. However, several unanswered questions remain, and future studies need to focus on correlating changes in 5-HT neurotransmission in both pathological and in vivo imaging studies with a full clinical phenotype.

DOI: 10.1002/mds.22473
PubMed: 19412960

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001D25

Links to Exploration step

pubmed:19412960

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serotonin and Parkinson's disease: On movement, mood, and madness.</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name>
<affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Clinic, University of Toronto, Toronto Western Hospital, Ontario, Canada. sfox@uhnresearch.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Clinic, University of Toronto, Toronto Western Hospital, Ontario</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chuang, Rosalind" sort="Chuang, Rosalind" uniqKey="Chuang R" first="Rosalind" last="Chuang">Rosalind Chuang</name>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M" last="Brotchie">Jonathan M. Brotchie</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="doi">10.1002/mds.22473</idno>
<idno type="RBID">pubmed:19412960</idno>
<idno type="pmid">19412960</idno>
<idno type="wicri:Area/PubMed/Corpus">001D25</idno>
<idno type="wicri:Area/PubMed/Curation">001D25</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Serotonin and Parkinson's disease: On movement, mood, and madness.</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name>
<affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Clinic, University of Toronto, Toronto Western Hospital, Ontario, Canada. sfox@uhnresearch.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Clinic, University of Toronto, Toronto Western Hospital, Ontario</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chuang, Rosalind" sort="Chuang, Rosalind" uniqKey="Chuang R" first="Rosalind" last="Chuang">Rosalind Chuang</name>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M" last="Brotchie">Jonathan M. Brotchie</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Affect (physiology)</term>
<term>Animals</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Humans</term>
<term>Mental Disorders (complications)</term>
<term>Mental Disorders (metabolism)</term>
<term>Movement (physiology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Serotonin (metabolism)</term>
<term>Serotonin Agents (adverse effects)</term>
<term>Serotonin Agents (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Serotonin Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Serotonin</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Mental Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Mental Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Affect</term>
<term>Movement</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Serotonin Agents</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">An appreciation of the multiple roles that serotonin (5-HT) may play in Parkinson's disease (PD) has increased in recent years. Early pathological studies in PD demonstrated nonselective reductions of 5-HT in brain tissue but little correlation to comorbidities such as dyskinesia and mood disturbance. This, combined with treatment failures using serotonergic drugs in comparison to levodopa, meant the field was largely neglected until recently. The multitude of subtypes of 5-HT receptors in the brain and an increased understanding of the potential function 5-HT may play in modulating other neurotransmitter systems, including dopamine, GABA, and glutamate, have meant an expansion in efforts to develop potential serotonergic drugs for both motor and nonmotor symptoms in PD. However, several unanswered questions remain, and future studies need to focus on correlating changes in 5-HT neurotransmission in both pathological and in vivo imaging studies with a full clinical phenotype.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19412960</PMID>
<DateCreated><Year>2009</Year>
<Month>08</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted><Year>2009</Year>
<Month>10</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>24</Volume>
<Issue>9</Issue>
<PubDate><Year>2009</Year>
<Month>Jul</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Serotonin and Parkinson's disease: On movement, mood, and madness.</ArticleTitle>
<Pagination><MedlinePgn>1255-66</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22473</ELocationID>
<Abstract><AbstractText>An appreciation of the multiple roles that serotonin (5-HT) may play in Parkinson's disease (PD) has increased in recent years. Early pathological studies in PD demonstrated nonselective reductions of 5-HT in brain tissue but little correlation to comorbidities such as dyskinesia and mood disturbance. This, combined with treatment failures using serotonergic drugs in comparison to levodopa, meant the field was largely neglected until recently. The multitude of subtypes of 5-HT receptors in the brain and an increased understanding of the potential function 5-HT may play in modulating other neurotransmitter systems, including dopamine, GABA, and glutamate, have meant an expansion in efforts to develop potential serotonergic drugs for both motor and nonmotor symptoms in PD. However, several unanswered questions remain, and future studies need to focus on correlating changes in 5-HT neurotransmission in both pathological and in vivo imaging studies with a full clinical phenotype.</AbstractText>
<CopyrightInformation>2009 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fox</LastName>
<ForeName>Susan H</ForeName>
<Initials>SH</Initials>
<AffiliationInfo><Affiliation>Movement Disorders Clinic, University of Toronto, Toronto Western Hospital, Ontario, Canada. sfox@uhnresearch.ca</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chuang</LastName>
<ForeName>Rosalind</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Brotchie</LastName>
<ForeName>Jonathan M</ForeName>
<Initials>JM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018490">Serotonin Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>333DO1RDJY</RegistryNumber>
<NameOfSubstance UI="D012701">Serotonin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000339">Affect</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D001523">Mental Disorders</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009068">Movement</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000502">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012701">Serotonin</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018490">Serotonin Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>151</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>5</Month>
<Day>5</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>5</Month>
<Day>5</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>10</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.22473</ArticleId>
<ArticleId IdType="pubmed">19412960</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D25 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001D25 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:19412960
   |texte=   Serotonin and Parkinson's disease: On movement, mood, and madness.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:19412960" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Serotonin and Parkinson's disease: On movement, mood, and madness.

Serotonin and Parkinson's disease: On movement, mood, and madness.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki